Collectively, these studies lead us to ask whether RXR/PPAR and RXR/NURR1 complexes are destabilized in the experimental PD model and whether the delivery of exogenous RXR to the PD brain activates PPARs and/or NURR1, providing an effective interventional treatment aimed at controlling inflammatory response and reversing PD pathobiology. Here, NR4A2 is linked to Parkinson disease.